Severe Ocular Steven–Johnson Syndrome due to Lenalidomide Therapy

To report a rare case of severe Stevens‐Johnson Syndrome (SJS) induced by lenalidomide therapy in a patient undergoing treatment for multiple myeloma. A 50‐year‐old female with a known diagnosis of multiple myeloma, undergoing chemotherapy for the past four months, presented with sudden‐onset extensive erythematous rashes and skin desquamation involving the entire body. Symptoms began one day after the administration of lenalidomide. On general examination, her vital parameters were stable. Dermatological findings included widespread epidermal detachment. Ocular examination revealed preserved visual acuity; however, there was marked desquamation of the eyelids, matted eyelashes, inflamed lid margins with ectropion, and developing conjunctival symblephara. A diagnosis of Stevens‐Johnson Syndrome was established. The patient was managed conservatively with intravenous fluids, antihistamines, and systemic antibacterial therapy. Significant clinical improvement was observed over the subsequent five days. Lenalidomide, although rarely reported, can be a potential trigger for severe SJS. Prompt recognition and early supportive therapy are crucial for preventing long‐term sequelae, especially ocular complications.